155 related articles for article (PubMed ID: 16715412)
1. Anti-SARS drug screening by molecular docking.
Wei DQ; Zhang R; Du QS; Gao WN; Li Y; Gao H; Wang SQ; Zhang X; Li AX; Sirois S; Chou KC
Amino Acids; 2006 Jul; 31(1):73-80. PubMed ID: 16715412
[TBL] [Abstract][Full Text] [Related]
2. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS.
Chou KC; Wei DQ; Zhong WZ
Biochem Biophys Res Commun; 2003 Aug; 308(1):148-51. PubMed ID: 12890493
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points.
Sirois S; Wei DQ; Du Q; Chou KC
J Chem Inf Comput Sci; 2004; 44(3):1111-22. PubMed ID: 15154780
[TBL] [Abstract][Full Text] [Related]
4. Progress in computational approach to drug development against SARS.
Chou KC; Wei DQ; Du QS; Sirois S; Zhong WZ
Curr Med Chem; 2006; 13(27):3263-70. PubMed ID: 17168850
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies of peptide drug candidates against SARS.
Zhang R; Wei DQ; Du QS; Chou KC
Med Chem; 2006 May; 2(3):309-14. PubMed ID: 16948478
[TBL] [Abstract][Full Text] [Related]
6. From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus.
Dooley AJ; Shindo N; Taggart B; Park JG; Pang YP
Bioorg Med Chem Lett; 2006 Feb; 16(4):830-3. PubMed ID: 16325400
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor design for SARS coronavirus main protease based on "distorted key theory".
Du QS; Sun H; Chou KC
Med Chem; 2007 Jan; 3(1):1-6. PubMed ID: 17266617
[TBL] [Abstract][Full Text] [Related]
8. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
9. Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study.
Wang L; Bao BB; Song GQ; Chen C; Zhang XM; Lu W; Wang Z; Cai Y; Li S; Fu S; Song FH; Yang H; Wang JG
Eur J Med Chem; 2017 Sep; 137():450-461. PubMed ID: 28624700
[TBL] [Abstract][Full Text] [Related]
10. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
Amin SA; Banerjee S; Gayen S; Jha T
Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
[TBL] [Abstract][Full Text] [Related]
11. "Teaching old drugs to kill new bugs": structure-based discovery of anti-SARS drugs.
Rajnarayanan RV; Dakshanamurthy S; Pattabiraman N
Biochem Biophys Res Commun; 2004 Aug; 321(2):370-8. PubMed ID: 15358186
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV).
Chu CK; Gadthula S; Chen X; Choo H; Olgen S; Barnard DL; Sidwell RW
Antivir Chem Chemother; 2006; 17(5):285-9. PubMed ID: 17176633
[TBL] [Abstract][Full Text] [Related]
13. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
14. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.
Lu IL; Mahindroo N; Liang PH; Peng YH; Kuo CJ; Tsai KC; Hsieh HP; Chao YS; Wu SY
J Med Chem; 2006 Aug; 49(17):5154-61. PubMed ID: 16913704
[TBL] [Abstract][Full Text] [Related]
15. Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.
Deeks HM; Walters RK; Barnoud J; Glowacki DR; Mulholland AJ
J Chem Inf Model; 2020 Dec; 60(12):5803-5814. PubMed ID: 33174415
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
17. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.
Xiong B; Gui CS; Xu XY; Luo C; Chen J; Luo HB; Chen LL; Li GW; Sun T; Yu CY; Yue LD; Duan WH; Shen JK; Qin L; Shi TL; Li YX; Chen KX; Luo XM; Shen X; Shen JH; Jiang HL
Acta Pharmacol Sin; 2003 Jun; 24(6):497-504. PubMed ID: 12791174
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs.
Anand K; Ziebuhr J; Wadhwani P; Mesters JR; Hilgenfeld R
Science; 2003 Jun; 300(5626):1763-7. PubMed ID: 12746549
[TBL] [Abstract][Full Text] [Related]
19. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
[TBL] [Abstract][Full Text] [Related]
20. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
